MET-CM101-100μg / 询价
MET-CM101-500μg / 询价
MET-CM101-500μgx2 / 询价
Cynomolgus HGF R/c-MET Protein
Recombinant Cynomolgus HGF R/c-MET Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Glu25-Asn930 [Accession | A0A2K5UM36].
The mature form of HGF R is a heterodimer which can be cleaved into α and β chain. The protein has a predicted MW of 32.5 kDa (α chain) and 69.9 kDa (β chain). Due to glycosylation, the protein migrates to 45-52 kDa (α chain) and 75-82 kDa (β chain) based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1EU per μg by the LAL method.
Lyophilized from 0.22μm filtered solution in PBS (pH 7.2). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Cynomolgus HGF R on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Cynomolgus HGF R is greater than 95% as determined by SEC-HPLC.
Immobilized Cynomolgus HGF R, His Tag at 5μg/ml (100μl/well) on the plate. Dose response curve for Anti-HGF R Antibody, hFc Tag with the EC50 of 7.2ng/ml determined by ELISA (QC Test).
c-Met, also called tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR), is a protein that in humans is encoded by the MET gene.The protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1.
MET; oncogene MET; HGF R; HGF/SF receptor; AUTS9; cMET; Met (c-Met); RCCP2; SF receptor
(1)Sierra J. c-MET as a potential therapeutic target and biomarker in cancer[J]. Therapeutic Advances in Medical Oncology, 2011, 3(1 Suppl):21-35.
